Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...

As described in a recent JAMA Viewpoint, the proposed national HCV elimination program intends to engage underserved populations in need of HCV treatment by working closely with grassroots ...

Atea Pharmaceuticals (NASDAQ:AVIR) used its presentation at the 44th Annual JPMorgan Healthcare Conference to provide updates on its global Phase 3 program for hepatitis C (HCV) and to outline early ...

Please provide your email address to receive an email when new articles are posted on . Among 133,732 veterans with HCV, 80.1% initiated treatment and 91.6% achieved SVR. Younger veterans were less ...

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

Atea Pharmaceuticals, Inc. ( (AVIR)) has released its Q3 earnings. Here is a breakdown of the information Atea Pharmaceuticals, Inc. presented to its investors. Atea Pharmaceuticals, Inc. is a ...

Pills can cure infection with the hepatitis C virus (HCV), but getting the medication to patients who need treatment can be a challenge. Many patients with HCV use drugs such as methamphetamine or ...

Please provide your email address to receive an email when new articles are posted on . Georgia’s hepatitis C virus elimination program made significant progress in helping diagnose patients and begin ...

Regulus Therapeutics Inc. is halting development of its lead microRNA candidate, RG-101, an N-acetylgalactosamine (GalNAc)-conjugated asset targeting miR-122 in chronic hepatitis C virus (HCV), rather ...